|122.58||+1.55||+1.28%||Vol 950.18K||1Y Perf -5.52%|
|Oct 4th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||149.89||Analyst Rating||Hold 2.69|
|Potential %||22.28||Finscreener Ranking||★+ 43.87|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★+ 47.91|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★+ 60.70|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★★+ 41.24|
|Price Range Ratio 52W %||7.72||Earnings Rating||Sell|
|Market Cap||13.76B||Earnings Date||19th Oct 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||19th Oct 2023|
|Estimated EPS Next Report||2.20|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||677.93K|
|Avg. Monthly Volume||755.21K|
|Avg. Quarterly Volume||753.04K|
Quest Diagnostics Incorporated (NYSE: DGX) stock closed at 122.58 per share at the end of the most recent trading day (a 1.28% change compared to the prior day closing price) with a volume of 950.18K shares and market capitalization of 13.76B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 49000 people. Quest Diagnostics Incorporated CEO is Stephen H. Rusckowski.
The one-year performance of Quest Diagnostics Incorporated stock is -5.52%, while year-to-date (YTD) performance is -21.64%. DGX stock has a five-year performance of 18.63%. Its 52-week range is between 119.59 and 158.3356, which gives DGX stock a 52-week price range ratio of 7.72%
Quest Diagnostics Incorporated currently has a PE ratio of 15.30, a price-to-book (PB) ratio of 2.84, a price-to-sale (PS) ratio of 2.31, a price to cashflow ratio of 20.70, a PEG ratio of 0.34, a ROA of 9.95%, a ROC of 12.22% and a ROE of 21.12%. The company’s profit margin is 11.91%, its EBITDA margin is 21.40%, and its revenue ttm is $7.55 Billion , which makes it $66.29 revenue per share.
Of the last four earnings reports from Quest Diagnostics Incorporated, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.20 for the next earnings report. Quest Diagnostics Incorporated’s next earnings report date is 19th Oct 2023.
The consensus rating of Wall Street analysts for Quest Diagnostics Incorporated is Hold (2.69), with a target price of $149.89, which is +22.28% compared to the current price. The earnings rating for Quest Diagnostics Incorporated stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Quest Diagnostics Incorporated has a dividend yield of 1.73% with a dividend per share of $2.64 and a payout ratio of 14.00%.
Quest Diagnostics Incorporated has a Sell technical analysis rating based on Technical Indicators (ADX : 7.41, ATR14 : 1.88, CCI20 : -151.11, Chaikin Money Flow : -0.30, MACD : -2.62, Money Flow Index : 23.73, ROC : -4.11, RSI : 23.39, STOCH (14,3) : 14.85, STOCH RSI : 0.09, UO : 35.01, Williams %R : -85.15), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Quest Diagnostics Incorporated in the last 12-months were: Catherine T. Doherty (Option Excercise at a value of $3 531 472), Catherine T. Doherty (Sold 48 479 shares of value $7 166 991 ), Doherty Catherine (Sold 7 714 shares of value $1 085 730 ), Michael E. Prevoznik (Sold 6 762 shares of value $950 438 ), Michael J. Deppe (Option Excercise at a value of $1 667 197), Michael J. Deppe (Sold 30 994 shares of value $4 494 130 ), Prevoznik Michael (Sold 6 762 shares of value $950 438 ), Timothy M. Ring (Option Excercise at a value of $238 351), Timothy M. Ring (Sold 4 025 shares of value $596 933 )
Wed, 30 Aug 2023 12:43 GMT Quest Diagnostics AAVrh74 ELISA assay receives Breakthrough Device Designation- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.